From: Effect of COVID-19 on Kawasaki Disease: Decrease Age of Onset and Increase Skin Manifestation
Characteristics | Total (n = 76) | Group 1 (n = 32) | Group 2 (n = 44) | P value | Estimated Power (%) |
---|---|---|---|---|---|
Age | 5.03 | 4.38 | 5.50 | 0.044 | 29 |
Male% | 60% (n = 46) | 65% (n = 21) | 56% (n = 25) | 0.438 | 8 |
Hospital course (days) | 4.47 | 5.13 | 4.00 | 0.555 | 30 |
Conjunctivitis | 38 (50%) | 14 (43.8%) | 24 (52.2%) | 0.353 | 7 |
Lymphadenopathy | 27 (36%) | 9 (28.1%) | 18 (39.1%) | 0.250 | 11 |
Oral mucosa or lips changes | 44 (58%) | 16 (50%) | 28 (60%) | 0.160 | 9.1 |
Rash | 47 (62%) | 19 (59%) | 28 (60.1%) | 0.706 | 3.5 |
Extremity changes | 44 (58%) | 19 (59%) | 25 (54.3%) | 0.824 | 3.7 |
Abnormal echocardiography findings (regarding coronary arteries) | 33 (43%) | 11 (34%) | 12 (26%) | 0.534 | 7.4 |
ESR(mm/h) | 62.01 | 75.79 | 57.5 | 0.068 | 46.1 |
CRP (mg/L) | 55.00 | 50.39 | 58.25 | 0.707 | 10 |